突变体 ARID1A：点燃癌症免疫疗法。
Mutant ARID1A: igniting cancer immunotherapy.
发表日期：2024 Aug
作者：
Bujamin H Vokshi, Eneda Toska
来源：
TRENDS IN IMMUNOLOGY
摘要：
麦克斯韦等人。研究表明，ARID1A 缺失可通过 cGAS-STING 途径触发 I 型 IFN 反应，从而增强抗肿瘤免疫，从而促进 T 细胞浸润和细胞毒性。这些发现强调 SWI/SNF 抑制剂是一种通过潜在地将无反应肿瘤转化为反应者并推进癌症治疗方法来增强免疫治疗功效的策略。版权所有 © 2024 Elsevier Ltd. 保留所有权利。
Maxwell et al. show that ARID1A loss enhances antitumor immunity by triggering a type I IFN response through the cGAS-STING pathway, thereby promoting T cell infiltration and cytotoxicity. These findings highlight SWI/SNF inhibitors as a strategy to augment immunotherapy efficacy by potentially transforming non-responsive tumors into responders and advancing approaches to cancer treatment.Copyright © 2024 Elsevier Ltd. All rights reserved.